Cognitive decline in Parkinson disease
Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD).
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …
[HTML][HTML] Tau PET imaging in neurodegenerative tauopathies—still a challenge
The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …
Impact of multiple pathologies on the threshold for clinically overt dementia
Longitudinal clinical–pathological studies have increasingly recognized the importance of
mixed pathologies (the coexistence of one or more neurodegenerative and cerebrovascular …
mixed pathologies (the coexistence of one or more neurodegenerative and cerebrovascular …
[HTML][HTML] Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
KA Jellinger, AD Korczyn - BMC medicine, 2018 - Springer
Abstract Background Dementia with Lewy bodies (DLB) and Parkinson's disease dementia
(PDD), which share many clinical, neurochemical, and morphological features, have been …
(PDD), which share many clinical, neurochemical, and morphological features, have been …
[HTML][HTML] Interactions of pathological proteins in neurodegenerative diseases
Neurodegenerative diseases such as Alzheimer's disease (AD), frontotemporal lobar
degeneration (FTD), Lewy body disease (LBD), Parkinson's disease (PD), and amyotrophic …
degeneration (FTD), Lewy body disease (LBD), Parkinson's disease (PD), and amyotrophic …
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies
KA Jellinger - Journal of neural transmission, 2018 - Springer
Dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD), although
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia
MJ Pontecorvo, MD Devous, I Kennedy, M Navitsky… - Brain, 2019 - academic.oup.com
The advent of tau-targeted PET tracers such as flortaucipir (18F)(flortaucipir, also known as
18F-AV-1451 or 18F-T807) have made it possible to investigate the sequence of …
18F-AV-1451 or 18F-T807) have made it possible to investigate the sequence of …
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
CR Jack Jr, HJ Wiste, H Botha, SD Weigand… - Brain, 2019 - academic.oup.com
Large phenotypically diverse research cohorts with both amyloid and tau PET have only
recently come into existence. Our objective was to determine relationships between the …
recently come into existence. Our objective was to determine relationships between the …
Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies
J Xiang, Y Tao, Y Xia, S Luo, Q Zhao, B Li, X Zhang… - Cell, 2023 - cell.com
Synucleinopathies are characterized by the accumulation of α-synuclein (α-Syn) aggregates
in the brain. Positron emission tomography (PET) imaging of synucleinopathies requires …
in the brain. Positron emission tomography (PET) imaging of synucleinopathies requires …
[HTML][HTML] The development and validation of tau PET tracers: current status and future directions
N Okamura, R Harada, A Ishiki, A Kikuchi… - Clinical and translational …, 2018 - Springer
Purpose To provide an overview on positron emission tomography (PET) imaging of tau
pathology in Alzheimer's disease (AD) and other neurodegenerative disorders. Results …
pathology in Alzheimer's disease (AD) and other neurodegenerative disorders. Results …